# MiniMed Group, Inc. (MMED)

> Cited company facts from SEC filings, by Steadybase. Web page: https://steadybase.io/company/minimed-group-inc/ JSON: https://steadybase.io/company/minimed-group-inc.json Checked Nov 10, 2026. Latest filing read: Sep 14, 2026.

## Company

- Legal name: MiniMed Group, Inc.
- Ticker: MMED, MMEDV (Nasdaq, Nasdaq)
- SEC CIK: 0002062583
- Industry: Surgical & Medical Instruments & Apparatus (SIC 3841)
- Headquarters: Northridge, CA
- Fiscal year ends: December 31
- SEC filer category: Non-accelerated filer
- Website: minimed.com
- Investor relations: https://investors.minimed.com
- LinkedIn: https://www.linkedin.com/company/minimed-diabetes
- Next earnings date: Nov 24, 2026

## Key facts

- Revenue: $3.1B for the fiscal year ended Apr 24, 2026 (10-K filed Jun 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026045915/0001628280-26-045915-index.html
- Operating income: -$190.0M for the fiscal year ended Apr 24, 2026 (10-K filed Jun 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026045915/0001628280-26-045915-index.html
- Net income: -$333.0M for the fiscal year ended Apr 24, 2026 (10-K filed Jun 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026045915/0001628280-26-045915-index.html
- SG&A: $1.2B for the fiscal year ended Apr 24, 2026 (10-K filed Jun 29, 2026). Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026045915/0001628280-26-045915-index.html
- Employees: 8,000 as of Apr 24, 2026, as reported in an SEC filing. Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026045915/mdt-20260424.htm
- Shares outstanding: 281,349,931 as of Sep 3, 2026 (10-Q filed Sep 8, 2026). Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026060926/0001628280-26-060926-index.html
- Auditor: Pricewaterhousecoopers LLP, Minneapolis, Minnesota, named in the latest 10-K. Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026045915/mdt-20260424.htm

## Business

We are a scaled global medical technology company that develops, manufactures, and markets a comprehensive suite of solutions for the management of diabetes. Since our founding more than 40 years ago, we have pioneered groundbreaking innovation and served the needs of our customers across the globe in service of our mission to make every day a better day for people with diabetes.

Source: Item 1. Business, https://www.sec.gov/Archives/edgar/data/2062583/000162828026045915/mdt-20260424.htm

## Annual results

| Fiscal year ended | Revenue | Operating income | Net income | SG&A |
|---|---|---|---|---|
| Apr 24, 2026 | $3.1B | -$190.0M | -$333.0M | $1.2B |
| Apr 25, 2025 | $2.7B | -$146.0M | -$213.0M | $1.1B |
| Apr 26, 2024 | $2.5B | -$69.0M | -$112.0M | $1.1B |

Each figure comes from the annual report for that year. Filing links for every figure: https://steadybase.io/company/minimed-group-inc.json

## Officers and directors

- Que Dallara, Chief Executive Officer. Source: Form 4 filed Aug 4, 2026, https://www.sec.gov/Archives/edgar/data/2062583/000175665226000004/0001756652-26-000004-index.htm
- Chad Spooner, EVP, Chief Financial Officer. LinkedIn: https://linkedin.com/in/chadspooner. Source: Form 4 filed Jul 29, 2026, https://www.sec.gov/Archives/edgar/data/2062583/000211146526000004/0002111465-26-000004-index.htm
- Christopher Eso, President. Source: Form 3 filed Mar 5, 2026, https://www.sec.gov/Archives/edgar/data/2062583/000162828026015436/0001628280-26-015436-index.htm
- Ali Dianaty, EVP Ch. Prod. & Tech Officer. LinkedIn: https://linkedin.com/in/ali-dianaty-88a265. Source: Form 4 filed Aug 4, 2026, https://www.sec.gov/Archives/edgar/data/2062583/000211149226000004/0002111492-26-000004-index.htm
- Gillian Chandrasena, SVP, Chief HR Officer. LinkedIn: https://linkedin.com/in/gillianchandrasena. Source: Form 4 filed Jul 29, 2026, https://www.sec.gov/Archives/edgar/data/2062583/000211146626000004/0002111466-26-000004-index.htm
- John Gyurci, VP, Chief Accounting Officer. LinkedIn: https://linkedin.com/in/john-gyurci-89bab81. Source: Form 4 filed Jul 6, 2026, https://www.sec.gov/Archives/edgar/data/2062583/000185068826000003/0001850688-26-000003-index.htm
- Sheila A. Denton, SVP, Gen. Counsel & Corp. Sec.. Source: Form 4 filed Oct 5, 2026, https://www.sec.gov/Archives/edgar/data/2062583/000199529826000009/0001995298-26-000009-index.htm
- Kevin E. Lofton, Board member (per proxy). Source: DEF 14A filed Aug 21, 2026, https://www.sec.gov/Archives/edgar/data/2062583/000114036126034021/ny20073045x1_def14a.htm

## Recent 8-K events

- Oct 16, 2026: Item 5.01, Changes in control of registrant; Item 5.02, Departure or appointment of directors or officers; compensation; Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2062583/000110465926116441/tm2627653d1_8k.htm
- Oct 13, 2026: Item 5.07, Submission of matters to a vote of security holders; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2062583/000110465926115141/tm2627388d1_8k.htm
- Sep 1, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026059699/mmed-20260901.htm
- Aug 5, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2062583/000110465926091115/tm2622265d1_8k.htm
- Jun 29, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 5.08, Item 5.08; Item 8.01, Other events; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2062583/000110465926078588/tm2619270d1_8k.htm
- Jun 3, 2026: Item 2.02, Results of operations and financial condition (earnings release); Item 7.01, Regulation FD disclosure; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026040036/mmed-20260603.htm
- May 18, 2026: Item 5.02, Departure or appointment of directors or officers; compensation; Item 9.01, Financial statements and exhibits. Source: https://www.sec.gov/Archives/edgar/data/2062583/000110465926063267/tm2614921d1_8k.htm
- Apr 27, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/2062583/000110465926049045/tm2612783d1_8k.htm
- Mar 27, 2026: Item 5.02, Departure or appointment of directors or officers; compensation. Source: https://www.sec.gov/Archives/edgar/data/2062583/000110465926036112/tm2610044d1_8k.htm
- Mar 25, 2026: Item 7.01, Regulation FD disclosure. Source: https://www.sec.gov/Archives/edgar/data/2062583/000110465926034156/tm269779d1_8k.htm

## What management said

- "MiniMed delivered an excellent start to our fiscal year, with accelerating U.S. growth, continued double-digit international growth, and strong execution across our innovation pipeline" Executive Officer Que Dallara, MiniMed Chief (8-K filed Sep 1, 2026). Source: https://www.sec.gov/Archives/edgar/data/2062583/000162828026059699/exhibit991-fy27q1earningsr.htm

## Latest filings

- 8-K filed Oct 16, 2026: https://www.sec.gov/Archives/edgar/data/2062583/000110465926116441/tm2627653d1_8k.htm
- 10-K filed Jun 29, 2026: https://www.sec.gov/Archives/edgar/data/2062583/000162828026045915/mdt-20260424.htm
- 10-Q filed Sep 8, 2026: https://www.sec.gov/Archives/edgar/data/2062583/000162828026060926/mdt-20260731.htm
- DEF 14A filed Aug 21, 2026: https://www.sec.gov/Archives/edgar/data/2062583/000114036126034021/ny20073045x1_def14a.htm

## About this data

SEC EDGAR filings, read by Steadybase. Every value links to the filing it came from.
Steadybase covers US-headquartered public companies that file with the SEC. API and MCP access: https://steadybase.io/docs/